Evidence map›Paper›PMID 30043334›Full record

Trial reportInternational journal of hematology2018

Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma.

Yoshihiro Kameoka, Tomoaki Akagi, Kazunori Murai, Hideyoshi Noji, Yuichi Kato, Osamu Sasaki, Shigeki Ito, Kenichi Ishizawa, Yoji Ishida, Ryo Ichinohasama and 2 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Yoshihiro KameokaDepartment of Hematology, Nephrology and Rheumatology, Akita University, 44-2 Hasunuma Hiroomote, Akita city, Akita, 010-0041, Japan. ykameoka@doc.med.akita-u.ac.jp.ORCID http://orcid.org/0000-0002-6786-3439
Tomoaki AkagiDepartment of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan.
Kazunori MuraiDepartment of Hematology and Oncology, Iwate Medical University, Morioka, Iwate, Japan.
Hideyoshi NojiDepartment of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan.
Yuichi KatoDepartment of Hematology, Yamagata University, Yamagata, Japan.
Osamu SasakiDepartment of Hematology, Miyagi Cancer Center, Natori, Miyagi, Japan.
Shigeki ItoDepartment of Hematology and Oncology, Iwate Medical University, Morioka, Iwate, Japan.
Kenichi IshizawaDepartment of Hematology, Yamagata University, Yamagata, Japan.
Yoji IshidaDepartment of Hematology and Oncology, Iwate Medical University, Morioka, Iwate, Japan.
Ryo IchinohasamaDepartment of Hemato-pathology, Tohoku University, Sendai, Miyagi, Japan.
Hideo HarigaeDepartment of Hematology and Rheumatology, Tohoku University, Sendai, Miyagi, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University, 44-2 Hasunuma Hiroomote, Akita city, Akita, 010-0041, Japan.
Iwate Medical University · JPAkita University · JPYamagata University · JPAomori Prefectural Central Hospital · JPFukushima Medical University · JPMiyagi Prefectural Hospital Organization · JPTohoku University · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is widely used as a salvage therapy for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL). To investigate the safety and efficacy of regimens including high-dose MCNU followed by ASCT for DLBCL, we analyzed the data from prospective multicenter trials. Twenty-nine patients were analyzed, and the median follow-up time for survival patients was 70 months. Fifteen patients received MCVC conditioning regimen, and fourteen patients received MEAM regimen. Major toxicities associated with these conditioning regimens included nausea (69%), anorexia (66%), febrile neutropenia (62%), diarrhea (59%), and mucositis (34%). One patient who developed severe sinusoidal obstructive syndrome and acute lung injury died without disease progression, and overall therapy-related mortality at 5 years was 3%. No patient developed therapy-related hematological malignancy. At 5 years, overall survival and progression-free survival in all patients were 82.8 and 58.2%, respectively. The 5-year OS in patients treated by the MCVC and MEAM regimens were 73.3 and 92.9%, respectively. These results suggest that regimens including high-dose MCNU followed by ASCT are feasible and effective for the treatment of relapsed or high-risk DLBCL. Further investigation is needed to evaluate of these regimens.

Indexed as

Stem Cell TransplantationAdultAutograftsDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNitrosourea CompoundsProspective StudiesSurvival RateNitrosourea CompoundsranimustineASCTDLBCLMCNU

Identifiers

PMID30043334
OpenAlexW2883650981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.